Stem cell based beta cell therapy - PanCryos
Alternative Names: PanINSULA™Latest Information Update: 07 Jun 2022
At a glance
- Originator PANCRYOS
- Class Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus